Gladys Maribel Hidalgo-Lozada

Dr. Gladys Maribel Hidalgo-Lozada

University of Guadalajara, Guadalajara, Jalisco, Mexico
+1
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Gladys Maribel Hidalgo-LozadaGladys Maribel Hidalgo-Lozada
Gladys Maribel Hidalgo-Lozada
ALAngélica Villarruel - López
Angélica Villarruel - López
KNKarla Nuño
Karla Nuño
AGAbel García-García
Abel García-García
Yaír Adonaí Sánchez-NuñoYaír Adonaí Sánchez-Nuño
Yaír Adonaí Sánchez-Nuño
César Octavio Ramos-GarcíaCésar Octavio Ramos-García
César Octavio Ramos-García
The prevalence and incidence of obesity and the comorbidities linked to it are increasing worldwide. Current therapies for obesity and associated pathologies have proven to cause a broad number of adverse effects, and often, they are overpriced or not affordable for all patients. Among the alternatives currently available, natural bioactive compounds stand out. These are frequently contained in pharmaceutical presentations, nutraceutical products, supplements, or functional foods. The clinical evidence for these molecules is increasingly solid, among which epigallocatechin-3-gallate, ellagic acid, resveratrol, berberine, anthocyanins, probiotics, carotenoids, curcumin, silymarin, hydroxy citric acid, and α-lipoic acid stand out. The molecular mechanisms and signaling pathways of these molecules have been shown to interact with the endocrine, nervous, and gastroenteric systems. They can regulate the expression of multiple genes and proteins involved in starvation–satiety processes, activate the brown adipose tissue, decrease lipogenesis and inflammation, increase lipolysis, and improve insulin sensitivity. This review provides a comprehensive view of nature-based therapeutic options to address the increasing prevalence of obesity. It offers a valuable perspective for future research and subsequent clinical practice, addressing everything from the molecular, genetic, and physiological bases to the clinical study of bioactive compounds.

28 September 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Gladys Maribel Hidalgo-LozadaGladys Maribel Hidalgo-Lozada
Gladys Maribel Hidalgo-Lozada
ALAngélica Villarruel - López
Angélica Villarruel - López
EAEsperanza Martinez Abundis
Esperanza Martinez Abundis
OVOlga Vázquez-Paulino
Olga Vázquez-Paulino
MGManuel González-Ortiz
Manuel González-Ortiz
KPKarina G Pérez-Rubio
Karina G Pérez-Rubio
Metabolic syndrome (MetS) is a cluster of cardiovascular risk factors, usually with a common pathophysiological origin in insulin resistance and abdominal obesity. Considering the reported effects of ellagic acid (EA) on insulin resistance and abdominal obesity, the aim of this study was to evaluate the effect of EA on the components of MetS, insulin sensitivity and insulin secretion by conducting a randomized, double-blind, placebo-controlled, clinical trial with 32 volunteers diagnosed with MetS. Sixteen patients were randomly allocated, received 500 mg of EA orally twice a day for 12 weeks, and the other 16 received a placebo. Clinical and laboratory determinations were obtained at baseline and at the end of the study. After EA administration, patients reduced their waist circumference (females: 102.2 ± 4.2 to 99.5 ± 3.2 cm (p < 0.05); males: 99.8 ± 6.7 to 96.0 ± 4.7 cm (p < 0.01)), systolic blood pressure (118.1 ± 10.1 to 113.7 ± 7.8 mmHg (p < 0.01)), diastolic blood pressure (118.1 ± 10.1 to 113.7 ± 7.8 mmHg (p < 0.01)), triglycerides (2.8 ± 1.1 to 2.1 ± 0.7 mmol/L (p < 0.01)), fasting plasma glucose (6.5 ± 0.5 to 5.7 ± 0.6 mmol/L (p < 0.01)), fasting plasma insulin (p < 0.01), and insulin secretion (p < 0.05), with an increase of insulin sensitivity (p < 0.01). In male patients, high-density lipoprotein cholesterol increased (p < 0.05). In conclusion, EA improved the components of MetS, reduced hyperinsulinemia, and improved insulin sensitivity.

31 January 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
Gladys Maribel Hidalgo-LozadaGladys Maribel Hidalgo-Lozada
Gladys Maribel Hidalgo-Lozada
ALAngélica Villarruel - López
Angélica Villarruel - López
KNKarla Nuño
Karla Nuño
AGAbel García-García
Abel García-García
Yaír Adonaí Sánchez-NuñoYaír Adonaí Sánchez-Nuño
Yaír Adonaí Sánchez-Nuño
César Octavio Ramos-GarcíaCésar Octavio Ramos-García
César Octavio Ramos-García
The prevalence and incidence of obesity and the comorbidities linked to it are increasing in the world population. Current therapies for obesity and associated pathologies have proven to cause a broad number of adverse effects and often, they are overpriced or not affordable for all patients. Among the alternatives currently available, natural bioactive compounds stand out. These are frequently contained in pharmaceutical presentations, nutraceutical products, supplements, or functional foods. The clinical evidence for these molecules is increasingly solid, among which epigallocatechin-3-gallate, ellagic acid, resveratrol, berberine, anthocyanins, probiotics, carotenoids, curcumin, silymarin, hydroxy citric acid, and α-lipoic acid stand out. The molecular mechanisms and signaling pathways of these molecules have been shown to interact with the endocrine, nervous, and gastroenteric systems, as well as regulate the expression of multiple genes and, therefore, proteins involved in starvation-satiety processes, activation of brown adipose tissue, increased lipolysis, decreased lipogenesis, and inflammation, beneficial changes in metabolism and improved insulin sensitivity. This review provides a comprehensive view of nature-based therapeutic options to address the increasing prevalence of obesity. It offers a valuable perspective for future research and subsequent clinical practice, addressing everything from the molecular, genetic, and physiological bases to the clinical study of the bioactive compound.